Trial Profile
A Phase I Pilot Study of Minnelide, A Novel Heat Shock Protein 70 Inhibitor, in Adult Patients With Relapsed or Refractory Acute Myeloid Leukemia
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Minnelide (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Sponsors Minneamrita Therapeutics
- 03 Mar 2018 Status changed from not yet recruiting to withdrawn prior to enrolment due to discordance in contractual language and terms.
- 22 Nov 2017 New trial record